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The human voltage-sensitive K+ channel hERG plays a fundamental role in cardiac action
potential repolarization, effectively controlling the QT interval of the electrocardiogram.
Inherited loss- or gain-of-function mutations in hERG can result in dangerous “long”
(LQTS) or “short” QT syndromes (SQTS), respectively, and the anomalous susceptibility of
hERG to block by a diverse range of drugs underlies an acquired LQTS. A recent open
channel cryo-EM structure of hERG should greatly advance understanding of the
molecular basis of hERG channelopathies and drug-induced LQTS. Here we describe
an update of recent research that addresses the nature of the particular gated state of
hERG captured in the new structure, and the insight afforded by the structure into the
molecular basis for high affinity drug block of hERG, the binding of hERG activators and
the molecular basis of hERG's peculiar gating properties. Interpretation of the
pharmacology of natural SQTS mutants in the context of the structure is a promising
approach to understanding the molecular basis of hERG inactivation, and the structure
suggests how voltage-dependent changes in the membrane domain may be transmitted
to an extracellular “turret” to effect inactivation through aromatic side chain motifs that are
conserved throughout the KCNH family of channels.
Keywords: hERG, cryo-EM structure, C-type inactivation, drug block, KCNH, long QT syndrome, short QT
syndrome, channelopathyTHE SIGNIFICANCE OF THE hERG POTASSIUM CHANNEL
The KCNH2 gene encodes a voltage sensitive potassium (K+) channel protein, hERG1 (“hERG” for
simplicity), which mediates rapid delayed rectifier K+ current (IKr) that makes a major contribution
to the repolarization phase of cardiac action potentials, effectively controlling the action potential
duration (APD) and QT interval observed in electrocardiograms (Sanguinetti and Tristani-Firouzi,
2006; Vandenberg et al., 2012). This cardiac function of hERG is a property of its unique gating
characteristics: like other voltage-sensitive K+ channels, hERG opens following membrane
depolarization as a result of voltage-dependent responses of its voltage sensor domain; however
the channel almost immediately inactivates, limiting K+ passage until the start of the repolarization
phase of the AP. In addition to the rapid onset and recovery from inactivation, hERG deactivates
very slowly so that outward K+ current is passed even as the membrane potential returns toward the
resting potential. This strongly supports efficient repolarization of the cardiac AP. The gating
kinetics of hERG also enable the channel to generate rapid transient currents late in action potential
repolarization/early diastole, to protect against arrhythmogenic premature depolarizations (Lu
et al., 2001). Additionally, the deactivation kinetics of the channel allow IKr to influence diastolicin.org January 2020 | Volume 10 | Article 15721
Butler et al. The Structure of hERGdepolarization of cardiac pacemaker cells (Ono and Ito, 1995;
Mitcheson and Hancox, 1999). Inherited mutations in hERG
that attenuate inactivation (“gain of function”) result in
premature repolarization and shortening of the QT interval
(short QT syndrome; SQTS) (Campuzano et al., 2019; Hancox
et al., 2019). Loss of function mutations, many (but not all) of
which arise from disrupted trafficking of hERG to the cell surface
(Anderson et al., 2014), can result in inefficient repolarization
and thus an elongation of the QT interval (long QT syndrome;
LQTS). Each of these may result in cardiac arrhythmias.
At least as important as its role in hERG-associated congenital
arrhythmias is the pharmacological susceptibility of hERG to
block by a variety of functionally- and structurally-diverse drugs
which underlies the drug-induced form of acquired LQTS with a
susceptibility to Torsades de Pointes (TdP) (Vandenberg et al.,
2001; Sanguinetti and Tristani-Firouzi, 2006; He et al., 2013;
Kalyaanamoorthy and Barakat, 2018). The potential for
involvement of hERG in drug-related arrhythmia is sufficiently
strong that existing preclinical guidelines require testing of all
new drugs for hERG block, typically using a hERG assay
(Hancox et al., 2008). Understanding the molecular basis for
promiscuous drug block of hERG would be enormously
beneficial in efforts to pre-screen drugs for hERG liability in
drug development programs, and to reduce adverse effects in
otherwise-useful drugs through targeted chemical modification.
Likewise, insight into the molecular basis for hERG's anomalous
gating properties, particularly the mechanisms of rapid onset and
recovery from inactivation, as well the perturbation of
inactivation in congenital short QT mutations, should greatly
facilitate development of therapeutic interventions for SQTS
(Hancox et al., 2018).
Considerable effort has been made to understand the
molecular basis of hERG's unique gating kinetics and
susceptibility to pharmacological inhibition. In the long
absence of a hERG structure, much of the functional data on
wild type hERG and channel mutants has been interpreted using
homology models of the channel (Villoutreix and Taboureau,
2015). In this light, a recent cryo-EM structure for hERG (Wang
and MacKinnon, 2017) is very welcome, providing the potential
to facilitate major advances in understanding hERG drug block
and the molecular basis for hERG channel gating. This short
review provides an update of progress in these areas some two
years after the publication of the structure, focusing on the
membrane domain of the channel that is most relevant to
hERG pharmacology. A recent review contains a good
overview of the structure of hERG's cytoplasmic domains
(Robertson and Morais-Cabral, 2019).THE hERG STRUCTURE AND DRUG
BLOCK
The hERG cryo-EM structure (PDB:5VA2; Figure 1) was
obtained using a truncated construct (hERGT) in which
cytoplasmic domain residues 141 to 350 and 871 to 1,005 were
removed from the full length 1,159 residue protein to suppressFrontiers in Pharmacology | www.frontiersin.org 2aggregation that occurs with wild type hERG (Wang and
MacKinnon, 2017). The first deletion removes most of the
linker region that connects the N-terminal Per-ARNT-Sim
(PAS) domain with the voltage sensor (VSD) domain (the
VSD S1 helix starts near P405, a short distance C-terminal to
W398, the first amino acid of the membrane domain visible in
the cryoEM structure; Figure 1). The second deletion eliminates
much of the long cytoplasmic C-terminal tail that follows the
cytoplasmic cyclic nucleotide binding homology domain
(CNBHD) that extends to near residue R863. Otherwise the
membrane domain of the channel is fully contained within the
hERGT construct, and this undergoes voltage-dependent
activation, fast inactivation, recovery from inactivation and
slow deactivation with properties much like WT hERG with
only a small (~5 mV) positive shift in the voltage-dependence of
inactivation. A second truncated construct (hERGTS;
PDB:5VA1) with residues 141–380 and 871–1,005 deleted,
served as a background for an S631A mutation (hERGTS
S631A; PDB:5VA3) that, like wild type hERG S631A, has
attenuated inactivation (see Figure 2 for the location of S631).
hERGTS has a voltage dependence of activation shifted around 20
mV to negative potentials but hERGTS S631A shows attenuated
inactivation relative to hERGTS analogous to the attenuation of
inactivation in hERG S631A relative to hERG, as described later.FIGURE 1 | Side view of the full hERG cryo-EM structure (PDB: 5VA2;
hERGT) with one of the four subunits colored by domain. PAS (the N-terminal
Per-ARNT-Sim) domain; the cytoplasmic C-linker links the S6 helix of the pore
domain (green) to the CNBHD (Cyclic Nucleotide Binding Homology Domain).
VSD (Voltage Sensor Domain). W398 is the first residue of the membrane
domain of hERG for which atom density is defined. Sequence breaks in some
extra extracellular loops are regions lacking atom density in the cryo-EM
structure. The horizontal black lines mark the approximate limits of the non-
polar part of the bilayer membrane.January 2020 | Volume 10 | Article 1572
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hERG structure, the absence of domain swapping amongst the
four subunits of the tetrameric membrane domain found in other
voltage-sensitive K+ channels (Figure 2), turns out not to be so
surprising since we were primed with a non-domain-swapped
structure of a related protein, EAG, published by Whicher and
MacKinnon in 2016 (Whicher and MacKinnon, 2016). The high
homology between hERG and EAG has allowed homology
models of hERG to be built on the EAG structural template
[e.g. (Butler et al., 2019)], and these suggested that two key amino
acid side chains in the channel pore domain known to be
important for drug block, Y652 and F656, likely project
towards the K+ permeation pathway to interact with hERG-
blocking drugs that diffuse into the pore when the channel opens
from the cytoplasmic side of the membrane (Figure 3A). It was a
surprise, therefore, to observe in the hERG open pore structure
that the F656 side chains project away from the K+ permeation
pathway towards the outer pore helix (S5; Figure 3B). Since
mutation of F656 has the largest effect in attenuating drug block
by a number of hERG blockers (Witchel et al., 2004; Kamiya
et al., 2006; Du et al., 2014; Melgari et al., 2015a; Helliwell et al.,
2018) (see Table 1), the expectation was that these blockers
interact with more than one F656 side chain, as observed in
computational docking with a variety of hERG pore models (e.g.
(Farid et al., 2006; Stansfeld et al., 2007; Stary et al., 2010;
Dempsey et al., 2014). This interpretation seems to be
incompatible with the arrangement of F656 side chains in the
cryoEM structure (Helliwell et al., 2018). On the other hand,
Wang and MacKinnon identified hydrophobic “pockets” that
project away from the central pore cavity below the selectivity
filter and pore helix (Figure 4) (Wang and MacKinnon, 2017);
these pockets provide potential interaction sites for hERG
blockers and there is no question that in computationalFrontiers in Pharmacology | www.frontiersin.org 3docking studies many well characterized hERG blockers can be
biased to bind partially within these pockets (e.g. Figure 4C).
However, when bound within a hydrophobic pocket, drugs are
able to interact with only one F656 side chain, contrary to the
expectations described above.
There are a couple of ways in which an apparent disparity
between experimental mutagenesis studies and the hERG
structure might be resolved. Firstly, the interpretation of
multiple F656 side chain interactions for blockers with high
F656-dependence might be mistaken and some of the high F656
dependence might relate to allosteric contributions of F656 to the
structure of the drug binding site. It has been suggested, for
example, that F656 might stabilize conformations of the Y652
side chain that promote strong interactions with blockers (Vaz
et al., 2017). However for several drugs, mutation of F656
produces much stronger attenuation of block than does
mutation of Y652 (see Table 1); block of hERG by flecainide,
for example, is relatively insensitive to mutation of Y652 to
alanine, whereas block is attenuated by nearly 150-fold in the
F656A mutant (Melgari et al., 2015a). Likewise using tandem
dimers in which pairs of hERG subunits are expressed as single
linked polypeptide chains, F656 side chains on two opposing
subunits could be mutated to Ala without effect on drug block of
several drugs (E-4031, terfenadine and cisapride) (Imai et al.,
2009). This indicates that at least two F656 side chains can be
changed to Ala without perturbing essential allosteric
contributions to a high-affinity drug binding site, although for
this selection of drugs, interaction with multiple F656 side
chains, if present, must involve two F656 side chains on
opposite subunits of the hERG tetrameric pore. A second
possibility is that the cryo-EM structure has been caught in a
conformation that is poorly compatible with high-affinity block.
hERG mutations that attenuate C-type inactivation alsoFIGURE 2 | (A) The hERG cryo-EM structure viewed from the extracellular side of the membrane illustrating the non-domain-swapped subunit organization in which the
voltage sensor domain (VSD) is packed against the pore domain of the same subunit. The long turret sequence containing a turret helix, that links the top of S5 with the N-
terminal end of the pore helix, is colored brown (some atom density in the non-helical region of the turret is missing in the cryo-EM structure and is modelled into the structure
shown). Polar side chains of N629 and S631 form a hydrogen-bonded ring that links subunits around the top of the selectivity filter. (B) Equivalent view of the Kv1.2/2.1 K+
channel chimera structure [KvChim; PDB: 2R9R (Long et al., 2007)] illustrating domain-swapping and a very short “turret” sequence (brown). Although the VSDs are packed
against pore domains of adjacent subunits in domain-swapped channels, the relative intersubunit juxtaposition of S5 and the pore helix with the VSD is similar to the
intrasubunit juxtaposition of VSD and S5 and pore helix in hERG (and rEAG). The purple sphere is a K+ ion in the S1 position of the selectivity filter.January 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERGattenuate binding of many high affinity hERG blockers, and
there is circumstantial evidence that competence for inactivation
in hERG is associated with repositioning of Y652 and (especially)
F656 side chains into a configuration that promotes interaction
with blockers in the pore (Chen et al., 2002). This might involve a
small clockwise rotation of the inner S6 helix containing these
side chains (Chen et al., 2002; Helliwell et al., 2018). In factFrontiers in Pharmacology | www.frontiersin.org 4modelling suggests that the structural rearrangement of the S6
helix required to reorient F656 into a pore-facing configuration
might be small (Helliwell et al., 2018), and a recent analysis of
ivabradine block of hERG using molecular dynamics (MD)
simulations supports some “flickering” of F656 side chains into
a pore-facing configuration involving, presumably, small
conformational changes in the S6 helices (Perissinotti et al.,TABLE 1 | Fold-change in IC50 relative to WT IC50 from alanine mutagenesis of hERG pore residues for selected hERG blockers.
hERG blocker Cell line Temp. WT IC50
(nM)
Fold Increase in IC50 (mutant IC50/WT IC50) Ref
Pore helix SF S6
T623A S624A V625A G648A Y652A F656A V659A
amiodarone HEK293 37°C 45 6.5 22 6
(E)
5.7 20 17 9.9 (Zhang et al., 2016)
Cavalli-2 HEK293 37°C 36 16 7 17 75 (Helliwell et al., 2018)
clomipramine HEK293
Oocyte
36 °C
room temp.
130
12,400 6 12
(Jo et al., 2008)
cisapride Oocyte room temp. 133 2 1 100 40 (Mitcheson et al., 2000)
clofilium Oocyte room temp. 30 12 381 250 1329 484 (Perry et al., 2004; Perry et al., 2006)
dofetilide
(estimated)
Oocyte room temp. 420 7 9 130 171 25 62 3 (Kamiya et al., 2006)
E-4031
(estimated)
Oocyte room temp. 570 4 13 86 40 31 89 4 (Kamiya et al., 2006)
flecainide HEK293 37 °C 1,490 5.6 1.8 27.5 8.9 3.4 141.5 (Melgari et al., 2015a)
ibutilide Oocyte room temp. 28 54 93 >300 140
(E)
67
(E)
140
(E)
18
(E)
(Perry et al., 2004)
MK-499 Oocyte room temp. 34 5 54 55 94 650 (Mitcheson et al., 2000)
ranolazine HEK293 37°C 8,030 19 8 8 22 53 (Du et al., 2014)
R-roscovitine Oocyte room temp. 196,000 5.4 0.8 2.9 42 (Cernuda et al., 2019)
terfenadine Oocyte room temp. 134 1.5 1.5 150 100 (Mitcheson et al., 2000)
verapamil HEK293
Oocyte
room temp. 143
5,100 16 20
(Zhang et al., 1999; Duan et al., 2007)
ziprasidone HEK293
Oocyte
37 °C
room temp.
120
2,800 140 357
(Su et al., 2006)Jan(E), estimated. The data report the effects on drug block of hERG mutations in pore helix residues, V625 in the selectivity filter (SF) or residues on the S6 helix. The fold increase in IC50
relative to its WT control is given as IC50 mutant/IC50 WT. Estimated fold increases in IC50 are tabled where experimentally derived IC50 values were not reported; the estimated values were
calculated using available single dose data, by using a standard Hill equation: Fractional block = 1/(1 + (IC50/[drug])
h), and assuming h = 1. Table updated from (Zhang et al., 2016).FIGURE 3 | (A) Bottom up view of the pore domain of a hERG homology model built on the structure of the highly homologous rEAG structure [PDB: 5K7L
(Whicher and MacKinnon, 2016)] which has an activated voltage sensor but a closed pore. In this model the side chains of key amino acids for hERG channel block,
Y652 and F656, are oriented towards the K+ permeation pathway at the centre of the pore. (B) In the open pore hERG cryo-EM structure, the F656 side chains are
oriented away from the pore center towards the F557 side chain on the S5 helix.uary 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERG2019). Further MD simulations should be useful in
characterising conformational excursions from the cryo-EM
structure that might support S6 aromatic side chain
interactions with blockers in the pore. In this regard, a recent
analysis of computational docking with MD simulations using
the cryoEM structure to compare calculated drug binding free
energies with experimental measures of drug block of hERG
suggests that this approach may be useful in allowing
conformational relaxation of the hERG drug binding site to
maximise interactions with drugs (Negami et al., 2019). Another
key piece of information might be obtained from concatemeric
hERG constructs used successfully by the Sanguinetti group, that
allow titration of side chain mutations separately to 1, 2, 3 or 4
subunits of the hERG tetramer (Wu et al., 2014; Wu et al., 2015);
comparing block of a hERG (pseudo) tetramer containing one or
two intact F656 side chains would resolve the question whether
the high dependence of some blockers on F656 indicates
interactions with more than one F656 side chain.
It should be said that the relationship between inactivation
and high-affinity drug block in hERG is not straightforward, and
the conclusion that high-affinity drugs bind more strongly to the
inactivated state per se, is not supported by recent evidence.
Sanguinetti's group demonstrated a dissociation of inactivation
from high-affinity block based on drug block in hERG
concatemers containing inactivation-attenuating mutations
S620T or S631A in one, two, three or four subunits (Wu et al.,
2015). As an example, although S620T mutation within a single
subunit attenuated hERG inactivation to an extent equivalent to
S620T mutation of all four subunits, the effect of these mutations
on block by cisapride, dofetilide and MK499 was graded
according to the number of subunits containing the S620T
mutation. Measurements on a “minimally-structured” high-
affinity blocker “Cavalli-2” (Cavalli et al., 2012) underFrontiers in Pharmacology | www.frontiersin.org 5conditions that promote the open, non-inactivated state or the
inactivated state, respectively, showed that Cavalli-2 does not
bind more strongly to the inactivated state of the wild-type
channel; this is the case despite substantial reductions in Cavalli-
2 block in S620T and N588K inactivation-attenuating mutants
(Helliwell et al., 2018). The N588K and S631A inactivation-
attenuating mutants are particularly interesting since the
conformational changes in the extracellular turret of hERG (in
N588K) and at the extracellular end of the selectivity filter (in
S631A) (see Figure 6) involved in disrupting hERG inactivation
must be transmitted to the cavity below the selectivity filter to
disrupt binding of some high-affinity blockers. Recently Thouta
et al. have argued for a dissociation of high-affinity drug block
from inactivation per se, using a mutation, I663P, that traps
hERG in an open state that nevertheless undergoes voltage-
dependent inactivation (Thouta et al., 2018). They found that the
extent of block of I663P hERG by terfenadine and cisapride was
effectively independent of whether block was sampled following
a holding potential of −80 mV (where inactivation is minimal) or
+40 mV (maximal inactivation).
Recent studies using unnatural amino acid analogues that
allow modulation of charge distribution within aromatic side
chains supports the interpretation that interactions of drugs with
canonical aromatic side chains Y652 and F656 involve aromatic
stacking interactions rather than cation-p interactions
(Macdonald et al., 2018), consistent with interpretations from
earlier computational docking studies (Imai et al., 2009;
Dempsey et al., 2014). The fact that high affinity drug blockers
that bind within the hERG pore have a positive charge centre
[normally a secondary, tertiary or quaternary (Perry et al., 2004;
Melgari et al., 2015a) amine] is likely a result of the negative
electrostatic potential below the selectivity filter resulting from
focusing of the pore-helix dipole charges that is particularlyFIGURE 4 | Comparison of the hERG pore cavity (A) with that of the Kv1.2/2.1 channel chimera (KvChim) (B). The hERG cavity is smaller than the equivalent
KvChim cavity and has hydrophobic “pockets” that project from the central cavity below the bottom of the selectivity filter and underneath the pore helix (PH). The
pore helix negative dipole charges focus a strong negative electrostatic potential below the selectivity filter which contributes to the binding energy for positively-
charged hERG pore blockers. (C) The hERG blocker “Cavalli-2” [(Cavalli et al., 2012); yellow space filling representation] can be docked partially within a hydrophobic
pocket although readjustment of F656 side chains is required for interaction of blocker with more than one F656 side chain [see text; adapted from (Helliwell et al.,
2018)]. Panels (A and B) from (Wang and MacKinnon, 2017) with permission.January 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERGstrong in hERG [(Wang and MacKinnon, 2017); see Figure 4A];
this makes a strong contribution to the binding and location of
positively-charged blockers in the hERG pore.
Support for binding of blockers within one of the
hydrophobic pockets below the pore helix comes from
observations that mutation of F557 on the outer pore helix
(S5) to F557L (hERG F557A is poorly-expressible (Ju et al.,
2009)) attenuates the effects of some hERG blockers (Saxena
et al., 2016). A direct interaction between blocker and F557
would seem to require that the blocker lies deep within a
hydrophobic pocket (see Figure 4C), and recently the
serotonin receptor (5HT1A) agonist and dopamine (D2)
receptor antagonist, sarizotan, was docked within a
hydrophobic pocket in a configuration consistent with
available mutagenesis data (Cheng et al., 2019). However
evidence remains equivocal about direct interactions between
drugs and F557; mutation of other residues that line the
hydrophobic pockets (F619 and L622; see Figure 4C) have
negligible (cisapride, haloperidol) or limited (dofetilide) effects
on block by these drugs (Saxena et al., 2016), and this is
surprising since computational docking indicates that drugs
that bind deep within a hERG pore hydrophobic pocket are
constrained within a compact binding site; as discussed below,
mutations of F619 and L622 strongly attenuate the effects of a
hERG activator, indicating that drug binding in this part of the
channel is expected to be susceptible to mutation of these side
chains. Likewise, for all drugs so far tested except cisapride, the
attenuation of block in F557L is similar to the effect of the hERG
Y652Amutation (Saxena et al., 2016; Helliwell et al., 2018; Cheng
et al., 2019; Perissinotti et al., 2019) suggesting that the
contributions of these side chains to hERG block may be
linked. This interpretation is reinforced by the finding that the
voltage-dependence of hERG block by Cavalli-2 is lost in hERG
F557L (Helliwell et al., 2018), similar to the loss of voltage-
dependence of block by this and other high-affinity blockers in
hERG Y652A (Sanchez-Chapula et al., 2003). Voltage-
dependence of hERG block resides in a voltage-dependent
change in the configuration of the Y652 side chain resulting
from interaction of the side chain phenolic OH dipole with the
membrane electric field as found in other channels and receptors
(Barchad-Avitzur et al., 2016). The Phe side chain cannot have
intrinsic voltage responsiveness and loss of voltage-dependence
of block in hERG F557L must result from an effect of the F557L
mutation on a residue, or part of the channel, that is voltage-
sensitive; a likely candidate is Y652. Wang and MacKinnon's
structure provides a context for addressing these uncertainties,
and a more detailed exploration of the effects of mutations of side
chains that line the hydrophobic “pockets” on drug block should
be productive.
The new hERG structure also provides a context for exploring
the structural basis for a potential alternative access of hERG
blockers to the central pore via the lipid bilayer, as recently
proposed for the bradycardic agent ivabradine (Lees-Miller et al.,
2015; Perissinotti et al., 2019). Many channel blockers, including
many hERG blockers, are lipophilic and are expected to partition
into the lipid bilayer phase; direct drug access from theFrontiers in Pharmacology | www.frontiersin.org 6membrane to the pore is well characterized for a number of
Nav (Payandeh et al., 2012) and twin-pore (K2P) channels (Dong
et al., 2015), although the fenestrations required for pore access
via the lipid are not well established in Kv channels (e.g.
(Jorgensen et al., 2016)). In neither the hERG nor EAG
structures is there a pathway that connects the central pore to
the membrane that is large enough for drug molecules to enter
via the membrane, and access via a lipid-facing fenestration
would seem to require either a conformational state of hERG not
represented in the new structures, considerable conformational
flexibility or conformational transitions associated with gating.
On the basis of a suppression of ivabradine block in hERG
M651T and modulation of F557 and F656 interactions by M651
in MD simulations (see Figure 4C for the location of these
residues) it is proposed that these three residues act as a dynamic
gate to facilitate ivabradine access from the membrane to the
inner pore (Perissinotti et al., 2019); however, direct evidence
from experiment or simulation for access to the pore [the likely
site of ivabradine channel block (Melgari et al., 2015b;
Perissinotti et al., 2019)] from the membrane remains to
be established.THE hERG STRUCTURE AND hERG
ACTIVATORS
In addition to drug block susceptibility, hERG is activated by sets
of molecules that act by attenuating inactivation and/or shifting
its voltage-dependence to depolarizing potentials, enhancing K+
conductance or slowing channel deactivation (or some
combination of these) (Sanguinetti, 2014). hERG activators
have promise in treating cardiac disorders involving hERG
dysfunction, for example the subset of long QT syndrome cases
arising from dysfunction of mutant channels that are trafficked to
the plasma membrane (Grunnet, 2010; Anderson et al., 2014).
One set of activators that comprises molecules containing a
negatively-charged group, exemplified in the case of hERG by
the activator PD-118057, has recently been shown to interact
promiscuously across a range of twin pore and voltage-sensitive
K+ channels (including hERG), to bind below the selectivity filter,
and suggested to promote K+ occupancy of sites within and below
the selectivity filter, enhancing channel conductance (Schewe et
al., 2019). PD-118057 was previously shown using mutagenesis to
interact with the hERG pore helix: PD-118057 activation of hERG
was effectively eliminated in hERG F619A, and L622C strongly
attenuated activation (Perry et al., 2009) (see Figures 4C and 5 for
the location of these residues). These studies provide strong
evidence that PD-118057 (and possibly other members of this
class of negatively-charged activators) occupy one or more (Wu
et al., 2014) of the hydrophobic pockets. Accordingly, it is possible
to find low energy score docked configurations for PD-118057
bound within a hydrophobic pocket with the negative carboxylate
group oriented to interact with K+ ions as they traverse the hERG
pore and enter the selectivity filter (Figure 5A). However, while
these configurations appear consistent with interpretations from
the structural analysis of negatively-charged activators with twinJanuary 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERGpore K+ channels (Schewe et al., 2019), they match less well with
the earlier mutagenesis data (Perry et al., 2009) that support a
binding of PD-118057 deeper within a pocket involving the pore
helix and residues on the S5-S6 interface (Figure 5B). Figure 5
illustrates what is essentially a geometric argument that, at least in
the context of the new cryo-EM structure, binding of PD-118057
within a hydrophobic pocket with its carboxylate oriented to
interact with K+ ions in the pore would seem to require
interaction with residues whose mutations have minimal effect
on binding [especially Y652; also F557 (Perry et al., 2009)], while
interacting less well with the residues deeper in the pocket that are
critical for binding [F619, L622 and L646 of an adjacent subunit
(Perry et al., 2009)].
In addition, while Schewe et al. propose an enhancement of
channel conductance arising from negative charge promotion of
occupation of K+ sites in or below the selectivity filter as a
mechanism for the activation of TREK channels by negatively
charged activators (Schewe et al., 2019), Perry et al. showed that
PD-118057 does not promote single channel conductance of
hERG, and that it acts largely by attenuating inactivation
(increasing channel open probability, Po), most likely by
suppressing conformational changes involving the pore helix
that are involved in hERG inactivation (Perry et al., 2009).
Interestingly, PD-118057 antagonises the blocking effect of at
least one potent hERG blocker, terfenadine, and while this may
suggest overlapping binding sites between activator and blocker
(Schewe et al., 2019), an alternative interpretation is that the
conformational changes associated with hERG inactivation that
are suppressed by PD-118057 are also linked to optimisation of
the configuration of side chains on the S6 helix (Y652 and F656)
for interaction with blockers in the channel pore (Chen et al.,
2002; Helliwell et al., 2018) as discussed above.Frontiers in Pharmacology | www.frontiersin.org 7LUF7244 is another hERG activator reported also to act
by attenuating rapid inactivation (Qile et al., 2019), that
suppresses binding of hERG inhibitors (cisapride, astemizole,
dofetililde and sertindole (Yu et al., 2016)). The potential of
hERG activators as therapeutics to counteract the effects of
drug-induced LQTS is shown by the recent demonstration
of suppression of dofetilide-induced torsades de pointes
arrhythmia in a dog model (Qile et al., 2019) by this
activator. LUF7244 can be docked into the hERG pore
domain of the cryo-EM structure between two subunits
and partly occupying a hydrophobic pocket in a manner
that might overlap with the binding site for dofetilide (Qile
et al., 2019) which is expected to lie largely in the K+
permeation pathway below the selectivity filter (Kamiya
et al., 2006). On the other hand, [3H]dofetilide binding
displacement by LUF7244 indicates that this activator is an
allosteric modulator of dofetilide binding with a distinct
(non-overlapping) binding site (Yu et al., 2016), and so
this activator might constitute an additional example where
the suppression of inactivation also suppresses inactivation-
associated conformational changes below the selectivity filter
that optimise high-affinity inhibitor binding. Consideration of
both inhibitor and activator binding therefore suggests that
the hERG cryo-EM structure may have been captured in a
pre-inactivated state which is optimal for binding of the
class of activators that suppress conformational transitions
that are involved in inactivation and which promote the
binding of some high-affinity pore blockers. The new
structure provides a context for addressing the interplay
between activator and inhibitor binding in this class of
hERG activators, and this should facilitate further
development of activators having therapeutic potential.FIGURE 5 | (A) PD-118057 (yellow sticks) can be docked into the hERG structure in configurations that orient the benzyl carboxyl group to interact with K+ ions as
they traverse the hERG conductance pathway as suggested in (Schewe et al., 2019). However in these configurations PD-118057 does not make favourable
interactions with F619, L622 (and L646 on the adjacent subunit), identified as key binding determinants for this activator (Perry et al., 2009). Also PD-118057 would
be expected to interact with Y652 and F557 in these states whereas mutagenesis of Y652 and F557 has minimal effect on activator binding (Perry et al., 2009).
(B) Docked states consistent with mutagenesis (Perry et al., 2009) (aromatic stacking and van der Waals interactions with F619, L622 and adjacent L646 side chain)
can be found deeper within the hydrophobic pockets below the pore helix, but these states are not compatible with interaction of the PD-118057 carboxylate with
K+ ions in the pore as suggested in (Schewe et al., 2019). To orient the viewer, PD-118057 occupies a hydrophobic pocket similar to that shown in Figure 4C for
Cavalli-2 binding, with the dichlorophenyl group (chlorine atoms green) of PD-118057 close to the membrane in panel B. Docking was performed with GOLD version
5.6; Cambridge Crystallographic Data Centre, Cambridge, UK as described previously (Dempsey et al., 2014; Helliwell et al., 2018).January 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERGTHE hERG STRUCTURE AND
CHANNEL GATING
Two features of hERG gating are of particular interest: (i) the
manner in which voltage-linked conformational changes in the
voltage sensor (VS) domain couple to the activation gate, and (ii)
the structural rearrangements that lead to the rapid C-type
inactivation that is a distinguishing feature of hERG. In the
first case the cryo-EM structure of hERG (and the earlier
structure of rEAG) provide the structural context for
rationalizing the curious observations that splitting of hERG
(Lorinczi et al., 2015; de la Pena et al., 2018) and EAG (Lorinczi
et al., 2015; Tomczak et al., 2017; Malak et al., 2019) in the S4–S5
linker between voltage sensor and pore domains yields channels
that open and close in response to changes in membrane
potential much l ike the wild type channels ; other
distinguishing features of these channels (e.g. inward
rectification/rapid inactivation in hERG; modulation of EAG
activation time constant by external Mg2+ and prepulse
potential) are broadly retained in the split channels (Lorinczi
et al., 2015). In both hERG and EAG the non-domain-swapped
organization and packing of VS domains against their own pore
subunits (see Figure 2) is associated with a very short S4–S5
linker sequence (Whicher and MacKinnon, 2016; Wang andFrontiers in Pharmacology | www.frontiersin.org 8MacKinnon, 2017) (Figure 6), and recent studies support one of
two possible mechanisms for VS-mediated closing of the hERG
activation gate at polarizing potentials that accommodates
retention of gating in split channels: (i) the S4–S5 linker acts
as a ligand that binds to the C-terminal end of the inner pore S6
helix below the activation gate, locking the channel in a closed
state. Upon depolarization upward movement of the S4 helix
pulls the linker out of its binding site on S6 allowing the pore to
open (Malak et al., 2017; Malak et al., 2019). (ii) The C-terminal
end of the S4 helix “pushes” on the bottom of the S6 helix in the
membrane polarized state closing the activation gate, and this
pushing is relieved by upward movement of S4 upon membrane
depolarization (Tomczak et al., 2017; de la Pena et al., 2018).
These mechanisms are similar in that they involve interaction of
elements at the bottom of the VS S4 helix and/or S4–S5 linker
with the C-terminal end of the S6 helix (Tristani-Firouzi et al.,
2002), and are consistent with evidence that the hERG pore is
“naturally” open in the absence of a membrane potential (e.g.
(Tristani-Firouzi et al., 2002)). In the cryo-EM structure the VSD
is in an activated configuration consistent with a depolarized
membrane potential (i.e. 0 mV in the conditions of cryo-EM),
with an open activation gate resulting from releasing the
constraints of S4 on the bottom of the S6 helix that are
described above. The S4 helix is therefore in an “upward”
configuration with the two S4 arginine side chains identified as
carrying gating charge (Arg 528 and Arg 531) (Zhang et al.,
2004) lying above the hydrophobic “plug” (Cheng et al., 2013)
that separates the intra-and extracellular hydrated segments of
the VSD. The structure of the VSD at repolarized potentials that
involves reconfiguration of S4 into a “downward” state is so far
structurally undefined. However, the fact that D540C in the short
S4–S5 linker forms a disulphide bond with L666C at the bottom
of S6 in the hERG D540C/L666C double mutant that locks the
activation gate closed indicates that these residues (D540 and
L666) are close together upon membrane repolarization (Ferrer
et al., 2006) (see Figure 6).
The most prominent feature of hERG gating is the rapid onset
of C-type inactivation at depolarized potentials, followed by
recovery from inactivation during the repolarization phase of
the action potential (see Sanguinetti and Tristani-Firouzi, 2006;
Vandenberg et al., 2012) for detailed descriptions of the hERG
gating cycle). This property combined with a slow channel
deactivation results in an efficient return to the cardiac
myocyte resting membrane potential. Like other K+ channels
hERG inactivation involves loss of K+ occupation of one or more
sites within the selectivity filter (Vandenberg et al., 2012;
Armstrong and Hollingworth, 2018). Comparison of the
selectivity filter in the hERG structure with that of EAG
(which doesn't inactivate) suggests that a ring of hydrogen
bonding side chains involving S631 and N629 on adjacent
subunits encircles the top of the selectivity filter (which
comprises the sequence S624VGFG628) and might act as a
compressible “spring” to modulate access and occupancy of the
outer site(s) of the selectivity filter (see Figure 2A), an
interpretation that is supported by an apparent change in
mode of binding of the scorpion toxin CnErg1 to directlyFIGURE 6 | Natural mutations (in brackets) in hERG that perturb inactivation
gating are found throughout the membrane domain indicating a network of
helix interactions that transmits conformational changes to the selectivity filter
(SF) resulting from mutation or voltage sensor (VS) activation. In the VS-
activated state captured in the cryo-EM structure, residues on S4 whose
mutation perturbs inactivation [e.g. L532P; (Hassel et al., 2008; Zhang et al.,
2011)] interact closely with side chains of the S1 helix. The extracytoplasmic
ends of the S1, S5 and pore helices interact via a cluster of aromatic side
chains (see also Figure 7). S5 and pore helix side chains interdigitate (‘knobs
into holes' packing) indicating a strong conformational coupling of these
helices. The locations of D540 and L666 that move close together upon
membrane repolarization are shown [adapted from (Butler et al., 2019)].January 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERG“plug” the selectivity filter in hERG S631A (Hill et al., 2007).
Replacing hERG S631 with alanine (in hERG S631A) to match
the equivalent EAG sequence was shown many years ago to
result in loss of inactivation (Schonherr and Heinemann, 1996);
this mutation has recently been found as a rare natural hERG
variant with a clinical manifestation of SQTS (Akdis et al., 2018).
The hERG cryo-EM structure is particularly valuable in
addressing the structural context of natural channel mutations
that underlie hERG-related channelopathies and the potential
this may afford for optimising therapeutic intervention with
hERG blocking antiarrhythmic agents (in the case of SQTS
(Hancox et al., 2018)) or activators in the case of LQTS
(Sanguinetti, 2014). Thus recent electrophysiological
characterization of the S631A mutation indicates that hERG
blockers like quinidine, with low dependence on inactivation
(lacking in hERG S631A), may be effective in suppressing
premature repolarization in this class of SQTS mutants (Butler
et al., 2018).
In the light of these observations, the cryo-EM structure of the
hERGTS S631A mutant construct published with the hERGT
structure (Wang and MacKinnon, 2017) is both fascinating and
puzzling. The S631A mutant structure differs from the hERGT
(and hERGTS) structure only by a small shift in the position of
the side chain of F627, which lies behind the selectivity filter, to a
configuration that closely matches the configuration of the
equivalent aromatic side chain in other Kv channels (e.g. EAG,
KcsA and KvChim; see (Wang and MacKinnon, 2017)). In other
words the position of F627 in hERGT and hERGTS is anomalous
in the context of other Kv channels (and hERGTS S631A) that
have more limited inactivation properties, leading to the
suggestion that hERGT (and hERGTS) represents an inactivated
state as would be expected in the absence of a membrane
potential (i.e. at 0 mV, well above the V0.5 for inactivation in
hERG) (Wang and MacKinnon, 2017). However, this seems
contrary to the expectations that inactivation in hERG is
associated (i) with conformational changes that are transmitted
to the region of the pore domain below the selectivity filter as
described earlier, and (ii) conformational changes involving the
hERG turret helix as described below. MD simulations may be
useful in establishing whether the configuration of F627 in the
hERG structure results in sufficient perturbation of the selectivity
filter to attenuate K+ ion occupancy as expected for an
inactivated state. If this is the case then the more extensive
conformational changes expected to be associated with hERG
inactivation might be subsequent events on the inactivation
pathway [see, e.g., (Wang et al., 2011)] that are not captured in
the cryo-EM structure.
The hERG structure also provides a context for exploring
the pathway(s) by which inactivation-gating develops upon
voltage-sensor activation, and again the study of natural
inactivation-perturbing hERG mutants is proving useful.
Recent consideration of the structural context of the
inactivation-attenuating I560T mutation that lies on the outer
pore (S5) helix suggests that conformational perturbation of the
S5 helix is likely to be linked to the selectivity filter via intimateFrontiers in Pharmacology | www.frontiersin.org 9interactions with the pore helix (Figure 6) (Butler et al., 2019).
In fact, inspection of several natural inactivation-perturbing
hERGmutations suggests that their effects are transferred to the
selectivity filter through a network of helix–helix interactions
involving the S4 and S1 helices of the voltage sensor domain
and the S5 and pore helices of the pore domain (Figure 6)
(Butler et al., 2019). This interpretation differs somewhat from
an inactivation pathway previously proposed that involves
direct interaction between the voltage sensor S4 helix and the
S5 helix (Perry et al., 2013). Although this is incompatible with
the cryo-EM structure, S4–S5 interactions might occur in
another gated state (e.g. the deactivated state at resting
membrane potentials). As described above, D540C forms a
disulphide bond with L666C in the hERG D540C/L666C
double mutant; since the S4–S5 linker is short, apposition of
D540 and L666 would seem to require a close approach of S4
and S5 at least at the cytoplasmic end of these helices when
membrane repolarization reconfigures the VS domain to close
the activation gate (see Figure 6).A “TRYPTOPHAN CLAMP” LINKING THE
S5 AND TURRET HELICES IN KCNH
CHANNELS?
A distinguishing feature of KCNH channels including the hERG
(KCNH2) and rEAG (KCNH1) variants for which structures are
now available (Whicher and MacKinnon, 2016; Wang and
MacKinnon, 2017), is a long amino acid sequence that links
the C-terminal end of the S5 helix and the N-terminal end of the
pore helix on the extracellular side of the channel (see Figures 1
and 2). Evidence that this “turret” region of KCNH channels
contains an amphipathic helix (Liu et al., 2002; Torres et al.,
2003) is confirmed in both the hERG (Figures 1 and 2A) and
rEAG structures; moreover the structures suggest how
conformational changes in the S5, pore helix and turret helices
may be connected to facilitate inactivation in hERG. The S5 and
turret helices are linked by pair of a stacked tryptophan side
chains (a “tryptophan clamp”) that interacts with a
phenylalanine side chain on the pore helix (Figure 7). This
arrangement is conserved, at least in amino acid sequence, across
the KCNH family (that also includes ELK channels) (Figure 7),
and is reminiscent of a similar structural motif that mediates
dimerization in the ligand binding domain of the human
pregnane X receptor (PXR) (Noble et al., 2006).
In hERG the turret helix is involved in fast C-type
inactivation, and mutations on the polar face of the turret
helix can attenuate [e.g. N588K (Brugada et al., 2004)] or
enhance (e.g. N588E) inactivation by shifting the voltage-
dependence to depolarizing or polarizing potentials,
respectively (Clarke et al., 2006). The tryptophan clamp likely
provides a structural link between the turret and the rest of the
channel that transmits conformational changes involving S5
and the pore helix, to the turret helix. In hERG this leads toJanuary 2020 | Volume 10 | Article 1572
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these are expected to involve reorientation of the turret helix
that allows residues on its polar face (N588 and Q592 in hERG)
to interact with polar groups on the top of the selectivity filter
(e.g. backbone and/or side chains of N629, S631, N633 and
T634 in hERG; see Figure 2). hEAG1 doesn't inactivate;
however a chimera with the S5P linker of EAG transplanted
into hERG inactivates with characteristics similar to hERG itself
(Herzberg et al., 1998), and inactivation can be recovered in
EAG1 by mutating residues equivalent to S620 and S631 in
hERG (T432 and A443 in bovine EAG1) to serine (Ficker et al.,
2001), indicating that the turret helix in EAG likely acts in an
equivalent manner to the hERG turret helix. Likewise, although
WT human (and bovine) EAG1 doesn't inactivate, the
drosophila version of EAG1 (dEAG1) does inactivate
(Robertson et al., 1996); surprisingly, dEAG1 has a lysine in
the equivalent position of the turret helix as N588 in hERG
(K409 in dEAG), substitution of which to lysine in hERG
(N588K; see Figure 6) strongly attenuates inactivation.
Interestingly, dEAG1 has an E462 at the homologous position
as N633 and, as indicated above, these residues at the top of the
selectivity filter may provide interacting “partners” for
complementary residues on the polar face of the turret helixFrontiers in Pharmacology | www.frontiersin.org 10when gating-induced conformational changes move the turret
helix closer to the top of the selectivity filter as suggested from
intersubunit disulphide bond formation in turret helix cysteine
mutants (Jiang et al., 2005). Altogether, these observations
support the conclusion that the turret helix responds similarly
across the KCNH family to gating-induced conformational
changes elsewhere in the protein [rELK2 rapidly inactivates
when its turret sequence is replaced by that of hERG (Clarke
et al., 2006)], with the specific modulating effect on gating (e.g.
rapid inactivation in hERG) depending on the particular amino
acid sequence of the turret helix and the amino acids near the
top of the selectivity filter that may interact with the turret at
specific depolarizing potentials. The new structures for hERG
and rEAG provide the structural context to explore and
understand these gating modulating mechanisms.CONCLUSIONS
Consideration of the cryo-EM structure of hERG in the context
of a large body of work obtained both before and following its
publication suggests that channel may have been captured in aFIGURE 7 | A “tryptophan clamp” connects the hERG turret helix with the top of the S5 helix. This motif that includes an interaction with F617 on the hERG pore
helix is conserved throughout the KCNH family of channels that includes ERG, EAG and ELK variants, despite considerable sequence diversity in the turret helix itself
(G584-I593 in hERG1). Helix interactions involving a cluster of aromatic side chains at the extracytoplasmic ends of S1, S5 and the pore helix may serve to anchor
the VS domain against the pore as observed in other Kv channels (Lee et al., 2009); dEAG1 is drosophila EAG1; h, human.January 2020 | Volume 10 | Article 1572
Butler et al. The Structure of hERGpre-inactivated open state, despite the expectation that hERG
should be largely inactivated at a membrane potential of zero
mV. Although this complicates understanding of the manner in
which high affinity drugs interact with the channel (since some
of these require conformational changes associated with
“inactivation-competence” for maximal binding affinity), it
suggests that the structure may be a good template for
optimising the design of the class of hERG activators that
suppress inactivation by binding and stabilising pre-inactivated
open states. The hERG and rEAG structures should also be useful
templates for molecular dynamics (MD) simulations to explore
the local structural and dynamic effects of natural mutations that
affect gating and the conformational changes involving linked
reconfiguration of the S5, pore- and turret-helices that modulate
gating in the KCNH family. As usual, it would be desirable to
have more structural information, and a wish-list would include
hERG structures complexed with a high affinity blocker, with an
inactivation-attenuating activator and a structure trapped in a
deactivated (resting) state. The latter is notoriously problematic
for voltage sensitive ion channels since these channels have
activated voltage sensors in the absence of a membrane
potential. In the case of hERG the D540C, L666C doubleFrontiers in Pharmacology | www.frontiersin.org 11mutant with a disulphide bond between the S4–S5 (D540C)
and S6 (L666C) helices might be a useful target for structural
analysis since this mutant is trapped in a closed state with the
voltage sensor presumably in its non-activated state (Ferrer et al.,
2006). However, for now the cryoEM structure for hERG is
providing a fascinating structural context for exploring and
interpreting a wealth of experimental data on this biophysically
and pharmacologically important channel.AUTHOR CONTRIBUTIONS
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